Association of the P441L KCNQ1 variant with severity of long QT syndrome and risk of cardiac events

Haoyang Lu, Wen Ding, Hui Xiao, Manyu Dai, Yangcheng Xue, Zhuoran Jia, Jie Guo, Mengzuo Wu, Bing Shen* and Ren Zhao*

1 Department of Cardiovascular Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China, 2 School of Basic Medical Sciences, Anhui Medical University, Hefei, China

Dysfunction of potassium voltage-gated channel subfamily Q member 1 (KCNQ1) is a primary cause of long QT syndrome type 1 (LQT1). Here, we report a missense mutation P441L in KCNQ1 C-terminus of a 37-year-old woman with severe LQT1 phenotype. Variant P441L transporting to the plasma membrane and interacting with KCNE1 were both markedly decreased, leading to potassium efflux disorder and eventually LQT1. Mutations between the C-terminal helix A and helix B of KCNQ1 have linked with low cardiac event risk, however, we firstly find variant P441L causing a severe LQT1 phenotype with a high risk of cardiac events.

KEYWORDS
long QT syndrome, KCNQ1, I_Ks, channel trafficking, C-terminus mutation

Introduction

Long QT syndrome (LQTS) is a hereditary heart disease caused by gene variants that lead to abnormal coding of channel proteins that cause prolonged myocardial repolarization time (1, 2). A prolonged QT interval on a surface 12-lead electrocardiogram (ECG) characterizes LQTS, often being in the form of torsade de pointes, which may lead to sudden cardiac death (3, 4). Type 1 LQTS (LQT1) is the most common type of congenital LQTS, accounting for approximately 45% of cases (5). Potassium voltage-gated channel subfamily Q member 1 (KCNQ1), encoded by the KCNQ1 gene, is an α subunit of a voltage-gated potassium (K^+) channel that forms a channel pore mediating K^+ efflux and cardiomyocyte repolarization in the plateau phase of cardiac action potentials. The KCNQ1 protein associates with the regulatory β subunit of potassium voltage-gated channel subfamily E regulatory subunit 1 (KCNE1) to mediate the slow delayed rectifier cardiac current (I_Ks) (6, 7). Dysfunction of KCNQ1 is a primary cause of LQT1 (8).
The C-terminal domain of the KCNQ1 gene contains four helical regions A–D, which are responsible for channel gating, assembly, and transport (9–11). Variants located at different positions of the gene are associated with varying degrees of severity in clinical symptoms. Therefore, it is particularly important to explore the associations between KCNQ1 genotype and clinical phenotype. In addition, identification of LQT1 pathogenesis may provide a reliable theoretical basis for treatment. In the present study, we identified a C-terminal KCNQ1 mutation (P441L) in a woman 37 years of age who was diagnosed as having LQTS with a severe clinical phenotype.

Materials and methods

Ethical considerations

This study was approved by the Institutional Review Committee of the First Affiliated Hospital of Anhui Medical University (PJ2021-14-34). The patient provided written informed consent before peripheral blood was collected. This study complies with the principles set forth in the Declaration of Helsinki.

Electrocardiogram analysis

A surface 12-lead ECG was synchronously traced with a Nalong-12PL electrocardiograph at a paper speed of 25 mm/s. The QT interval was determined from the start of the QRS wave to the end of the T wave.

KCNQ1 genomic analysis

Genomic DNA was isolated from the patient's peripheral blood leukocytes. Polymerase chain reaction and Sanger sequencing were performed. The forward primer was 5'-ATCTGCTTCCTGCTGTCCTG-3', and the reverse primer was 5'-TGGCTTGCTCGGGCTCCCAA-3'. The sequencing reaction was performed using an ABI 3730 DNA analyzer (Thermo Fisher Scientific, Waltham, MA). The obtained chromatograms were analyzed using Variant Reporter, version 1.1 (Applied Biosystems, Thermo Fisher Scientific).

Plasmid construction, point mutation, and transfection

The full-length cDNAs for KCNQ1 (GenBank NM_000218) and KCNE1 (GenBank NM_000219) were obtained using a high-fidelity polymerase chain reaction DNA polymerase (P505-d1, Novizan, China). The KCNQ1 cDNA was cloned into a pEGFP-N1 vector, and the KCNE1 cDNA was cloned into a pmCherry-N1 vector. We used a KCNQ1-EGFP plasmid as a template and a point mutation kit (C214-01, Novizan, China) to mutate the 1322nd base in the coding sequence region of the KCNQ1 gene from C to T, and the 441st amino acid from proline (P) to leucine (L). After the point mutations were completed, the sequences were transfected into human embryonic kidney (HEK293) cells.

Electrophysiology

We transferred glass coverslips with the transfected HEK293 cells to 500 μL of a solution containing (in mM) 150 NaCl, 5 KCl, 1 MgCl2, 2.5 CaCl2, 10 HEPES, and 10 glucose (pH 7.4, adjusted with NaOH). Glass pipette electrodes were pulled from borosilicate glass (1B150F-4, World Precision Instruments, USA) with a glass electrode puller (PC-100, Narishige, Japan), to a resistance of 3–5 MΩ. The intracellular solution used in the pipette contained (in mmol/L) 153 KCl, 1 MgCl2, 10 HEPES, 5 EGTA, and 4 Na2ATP (pH 7.2, adjusted with KOH). An EPC-9 amplifier controlled by PatchMaster software (HEKA, Lambrecht, Germany) was used to measure the whole-cell current of EGFP/mCherry–positive cells. The holding voltage was –80 mV.

Confocal microscopy

After transfection, HEK293 cells were incubated with endoplasmic reticulum (ER)-Tracker Red (C1041, Beyotime, China) at 37°C for 30 min and then fixed with 4% paraformaldehyde. Following three washouts with phosphate-buffered saline, 4',6-diamidino-2-phenylindole (DAPI) (C1005, Beyotime, China) was used to stain cell nuclei. HEK293 cells transiently transfected with KCNQ1-EGFP/KCNE1-mCherry and P441L-EGFP/KCNE1-mCherry were also stained with DAPI. An argon laser was used to excite EGFP and mCherry, and an oil microscope objective was used to image the cells. An LSM 880 (Leica, Germany) laser scanning confocal microscope was used to obtain merged images by superimposing images from different channels.

Co-immunoprecipitation and western blotting

Non-ident P-40 lysis buffer was added to lyse the cells. Protein A/G Magnetic Beads (HY-K0202, MedChemExpress, USA) and KCNQ1 antibody (sc-365186, Santa Cruz, USA) were incubated at 4°C for 2 h to allow for the formation of magnetic bead–antibody complexes. The supernatant was incubated with the magnetic bead–antibody complexes on a shaker at 4°C for 3 h.
FIGURE 1
Characterization of long QT syndrome type 1 in a patient with the P441L variant of KCNQ1 (potassium voltage-gated channel, subfamily Q member 1). (A) Patient electrocardiogram showing the corrected QT interval (QTc) interval is prolonged to 797 ms. (B) Sanger sequencing data showing the novel KCNQ1 mutation of C1322T in the P441L variant. Sequence analysis of genomic KCNQ1 obtained from the blood of the patient reveals a heterozygote missense mutation (C→T) at position 1322 of the KCNQ1 coding region (C1322T). (C) Schematic representation of KCNQ1 protein with the P441L variant; proline is replaced by leucine at position 441 of the cytoplasmic C-terminal domain (P441L). Created with BioRender.com. (D) Partial amino acid sequences of different species KCNQ1 homologs aligned at the position corresponding to tyrosine 441 of human KCNQ1 (arrow). Number, the position of the last amino acid of each partial sequence. The conserved motif is outlined in black.

After a washout, the obtained Co-IP product was resuspended in 100 µL of loading buffer and electrophoresed using 8% gels by sodium lauryl sulfate–polyacrylamide gel electrophoresis. The separated proteins were transferred to polyvinylidene fluoride membranes. The membrane was incubated with anti-KCNQ1 and anti-KCNE1 antibodies (DF6310, affinity, China) overnight at 4°C. After being rinsed, membranes were incubated with goat anti-rabbit and goat anti-mouse IgG horseradish peroxidase–conjugated secondary antibodies (1:5000) for 2 h at room temperature. Enhanced chemiluminescence substrate was used to detect the labeled secondary antibodies, and protein bands were quantified by densitometry using ImageJ software (National Institutes of Health, Bethesda, Maryland, USA).

Results

Clinical characteristics of the patient

The patient was admitted to the hospital with repeated syncope for 2 days without obvious inducement. ECG showed sinus rhythm with a heart rate of 56 beats per min (bmp) and a QTc interval of 797 ms (Figure 1A). She had not previously used QT-prolonging drugs. During hospitalization, the patient had three additional episodes of syncope accompanied by loss of consciousness, stiff limbs, and convulsions. ECG monitoring showed torsade de pointes ventricular tachycardia, which was terminated after electrical cardioversion, and a temporary pacemaker was implanted. The patient had no discomfort, fever, dyspnea, or chest pain. No electrolyte abnormalities were detected after admission. Physical examination and transthoracic echocardiography findings were within reference ranges. The diagnosis of LQT1 was performed by DNA sequence identifying an allelic missense mutation C1322T (Figure 1B).

Among mammalian homologs, the species of the amino acid corresponding to P441 of human KCNQ1 subunit are conserved, but not conserved in the KCNQ family (KCNQ2-5) (Figures 1C,D and Supplementary Figure 1).

Statistical analysis

Data are presented as means ± SEM. Statistical analyses were performed with GraphPad Prism, version 6 (GraphPad Software Inc.), and R (The R Foundation). We conducted two-tailed Mann–Whitney tests or two-way analyses of variance followed by Games–Howell post-hoc tests. Statistical significance was set at $P < 0.05$. 

Frontiers in Cardiovascular Medicine 03 frontiersin.org
FIGURE 2
KCNQ1 P441L variant protein trafficking in the absence or presence of KCNE1 (potassium voltage-gated channel subfamily E regulatory subunit 1), and the interaction between the KCNQ1 P441L variant and KCNE1 proteins. (A–C) Representative confocal microscopy images and line plots showing the cellular distribution of wild-type and P441L variant KCNQ1 proteins in HEK293 cells. Scale bar, 10 μm. KCNQ1 was tagged with (Continued)
Effects of variant P441L on KCNQ1 channel protein trafficking in the absence or presence of KCNE1 and the interaction between P441L and KCNE1

Previous studies have determined that EGFP fused to the KCNQ1 C-terminal end will not affect channel transport function (12). Our data showed that KCNQ1-EGFP (green fluorescence) was located on the cell membrane, but the P441L KCNQ1 variant was not observed in the cytoplasm (Figures 2A–C). To confirm this finding, we extract cell membrane proteins and cytoplasmic proteins, respectively. The results indicated that compared with the level of the KCNQ1-EGFP protein, the protein level of P441L-EGFP was significantly decreased on the cell membrane but increased in the cytoplasm (Figure 2D). The findings indicated that the channel subunit with variant P441L associated with LQTS in the patient was not transported to the cell membrane but remained in the ER.

In cardiomyocytes, the slowly activating delayed rectifier K+ current (I_{Ks}) channel complex is formed by the co-assembly of KCNQ1, KCNE1, and several auxiliary regulatory molecules (6, 13). We examined that in cells with P441L-EGFP/KCNE1-mCherry (Figures 2E–G), red fluorescence indicative of KCNQ1-mCherry was found predominantly in the cell membrane, but only weak green fluorescence indicative of P441L-EGFP was observed in the cell membrane. To confirm this finding, we extracted membrane and cytoplasmic proteins from co-expressed KCNQ1-EGFP/KCNE1-mCherry and P441L-EGFP/KCNE1-mCherry cells. A small amount of KCNQ1 protein in variant P441L expressing cells was detected in cell membranes (Figure 2H). The results indicated that the presence of KCNE1 facilitated variant P441L transport. In Co-IP experiment, compared with wild-type KCNQ1, the amount of pulled down KCNE1 with variant P441L was markedly reduced (Figures 2I,J). These findings suggested that variant P441L may affect the interaction between KCNQ1 and KCNE1. Even though KCNE1 may facilitate the transport of the variant to the membrane, KCNE1 does not completely rescue the dysfunction caused by variant P441L.

Electrophysiological characteristics of the KCNQ1 P441L variant channel

Previous studies have shown that expression of KCNQ1 with the C-terminus fused to EGFP produces currents that are not different from KCNQ1 (12, 14). We transiently transfected HEK293 cells with KCNQ1-EGFP or P441L-EGFP to form homomultimer channels. Results indicated that wild-type KCNQ1 exhibited relatively slowly activating and deactivating potassium currents in EGFP-positive cells under voltage clamp, but the cells with the P441L channel exhibited very small rapid activation currents (Figures 3A,B). When KCNQ1 and KCNE1 subunits were co-assembled, the current of the P441L-EGFP/KCNE1-mCherry channel was only half that of the KCNQ1-EGFP/KCNE1-mCherry channel (Figures 3C,D), but there is no statistical difference in channel opening speed and difficulty between the two groups (Supplementary Figure 2). This finding indicated that only a portion of the expressed P441L-EGFP/KCNE1-mCherry channels were located in the cell membrane.

Discussion

In this study, we found a KCNQ1 missense P441L mutation at the KCNQ1 C-terminus in a 37-year-old woman diagnosed as having LQT1. The patient’s ECG showed prolong QTc intervals, and she experienced stiff limbs and convulsions with loss of consciousness. Several previous studies have shown that KCNQ1 mutations may lead to LQT1 through two mechanisms: (1) the KCNQ1 channel protein loses the ability to correctly co-assemble or to be transported to the plasma membrane; and (2) the KCNQ1 channel is unable to mediate K+ flow across the plasma membrane (15–17).
We demonstrated that KCNQ1 variant P441L channel protein expressed in HEK293 cells was not transported to the plasma membrane but remained in the ER. Our whole-cell patch clamp results also indicated that HEK293 cells with the KCNQ1-P441L channel expressed did not have the same K⁺ current as cells with the wild-type channel. In addition, the interaction between the KCNQ1-P441L channel protein and KCNE1 was significantly reduced. Previous studies have shown that mutations in the C-terminus of KCNQ1 are mostly in helix C and helix D (T587M, R594Q, and G619D), which may interfere with the transport of ion channel proteins to the cell membrane, resulting in a corresponding loss of function (12, 18–20). However, the mechanism by which the mutation site between helix A and helix B leads
to LQT1 is unclear. The M437V mutation adjacent to the P441L mutation has been shown to affect the channel ion current mediated by KCNQ1 but it does not affect transport to the plasma membrane (21). However, we here firstly report that mutation located between helix A and helix B, markedly affected the transport of the channel subunits to the membrane and the interaction with KCNE1 and eventually led to severe LQT1.

Most of the KCNQ1 mutations associated with LQT1 are in the transmembrane segment, with only 31.2% of the pathogenic mutations in the C-terminus (4). In addition, compared with patients who have KCNQ1 mutations in the channel transmembrane region, many patients with C-terminal mutations have exhibited a lower risk of cardiac events beside T587M mutation at the C-terminus between helix C and helix D (10, 12, 22, 23). In our study, the clinical manifestations of variant P441L were severe in this patient. Genetic testing can provide valuable clinical information for long QT syndrome and provide some help in the diagnosis, treatment and prognosis of the disease, but we still have to consider the possible role of ethnicity, and the possible existence of mutations in other, untested genes should be weighed in the balance (24–26). Therefore, cardiologists stratifying risk of cardiac events should avoid discounting the pathogenic potential of C-terminal mutations in KCNQ1 because some of them, including and perhaps especially P441L, may induce a severe LQT1 phenotype with increased risk of cardiac events.

Conclusion

In conclusion, we demonstrated for the first time that the C-terminal mutation P441L, located between helix A and helix B in the KCNQ1 protein, may lead to severe LQT1 with increased risk of cardiac events, causes trafficking defect and affects the interaction between KCNQ1 and KCNE1.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the First Affiliated Hospital of Anhui Medical University (PJ2021-14-34). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

HL, WD, HX, BS, and RZ contributed to the design of the study. HL, WD, HX, MD, YX, ZJ, JG, and MW performed the experiments. BS and RZ supervised the project. HL, WD, BS, and RZ wrote the manuscript. All authors participated in revising the article and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81970446).

Acknowledgments

We thank the Center for Scientific Research of Anhui Medical University for valuable help in the experiment.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.922335/full#supplementary-material
1. Priori SG, Bloose R, Crotti L. The long QT syndrome. *Europace.* (2001) 3:16–27. doi: 10.1035/europ.2000.0141

2. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. *Circ Arrhythm Electrophysiol.* (2012) 5:868–77. doi: 10.1161/CIRCEP.111.962019

3. Roden DM. Clinical practice. Long-QT syndrome. *N Engl J Med.* (2008) 358:169–76. doi: 10.1056/NEJMep0706531

4. Moss AJ, Shimizu W, Wilde AA, Tobin JA, Zareba W, Robinson JL, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. *Circulation.* (2007) 115:2481–9. doi: 10.1161/CIRCULATIONAHA.106.665406

5. Wilde AA, Roden DM. Predicting the long-QT genotype from clinical data: sense from science to evidence. *Circulation.* (2008) 102:2796–8. doi: 10.1161/circulation.102.23-2796

6. Schow EV, Freites JA, Gogna K, White SH, Tobias DJ. Down-state model of the voltage-sensing domain of a potassium channel. *Biophys J.* (2010) 98:2857–66. doi: 10.1016/j.bpj.2010.03.031

7. Sanguinetti MC. Long QT syndrome: ionic basis and arrhythmia mechanism in long QT syndrome type 1. *J Cardiovasc Electrophysiol.* (2000) 11:710–2. doi: 10.1046/j.1540-8167.2000.tb00035.x

8. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, et al. Positional cloning of a novel potassium channel gene: KCNQ1 mutations cause cardiac arrhythmias. *Nat Genet.* (1996) 12:17–23. doi: 10.1038/ng0196-17

9. Haitin Y, Attali B. The C-terminus of Kv7 channels: a multifunctional module. *J Physiol.* (2008) 586:1803–10. doi: 10.1113/jphysiol.2007.149187

10. Dvir M, Peretz A, Haitin Y, Attali B. Recent molecular insights from mutated IKs channels in cardiac arrhythmia. *Curr Opin Pharmacol.* (2014) 13:74–82. doi: 10.1016/j.coph.2013.12.004

11. Wiener R, Haitin Y, Shangur L, Fernández-Alonso MC, Martos A, Chomsky-Hecht O, et al. The KCNQ1 (Kv7.1) COOH terminus, a multitiered scaffold for subunit assembly and protein interaction. *J Biol Chem.* (2008) 283:5815–30. doi: 10.1074/jbc.M707541200

12. Yamashita F, Horie M, Kubota T, Yoshida H, Yumoto Y, Kobori A, et al. Characterization and subcellular localization of KCNQ1 with a heterozygous mutation in the C terminus. *J Mol Cell Cardiol.* (2001) 33:197–207. doi: 10.1006/jmcc.2000.1300

13. Jost N, Virág L, Bitay M, Takács J, Lengyel C, Biliczki P, et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. *Circulation.* (2005) 112:1392–9. doi: 10.1161/CIRCULATIONAHA.105.550111

14. Wilson AJ, Quinn KV, Graves FM, Bittner-Glindzicz M, Tinker A. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndrome (LQT1). *Cardiovasc Res.* (2005) 67:876–86. doi: 10.1016/j.cardiores.2005.04.036

15. Moretti A, Bellin M, Welling A, Jung CR, Lam JT, Bott-Flügel L, et al. Patient-specific induced pluripotent stem cell models for long QT syndrome. *N Engl J Med.* (2010) 363:1397–409. doi: 10.1056/NEJMoa0908679

16. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsushita T, et al. Disease characterization using LQTS-specific induced pluripotent stem cells. *Cardiovasc Res.* (2012) 95:419–29. doi: 10.1093/cvrv/cks206

17. Chen J, Zheng R, Melman YF, McDonald TV. Functional interactions between KCNE1 C-terminus and the KCNQ1 channel. *PloS One.* (2009) 4:e5143. doi: 10.1371/journal.pone.0005143

18. Mosavari Nik A, Ghararie S, Kim HJ. Cellular mechanisms of mutations in Kv7.1: auditory functions in Jervell and Lange-Nielsen syndrome vs. Romano-Ward syndrome. *Front Cell Neurosci.* (2015) 9:32. doi: 10.3389/fncel.2015.00032

19. Gouas L, Belloq C, Berthet M, Pottet F, Demolombe S, Forhan A, et al. New KCNQ1 mutations leading to haploinsufficiency in a general populat Defective trafficking of a KvLQT1 mutant. *Cardiovasc Res.* (2004) 63:60–8. doi: 10.1016/j.cardiores.2004.02.011

20. Aromolaran AS, Subramaniam P, Chang DD, Kobertz WR, Colecraft HM. LQT1 mutations in KCNQ1 C-terminus assembly domain suppress IKs using different mechanisms. *Cardiovasc Res.* (2014) 104:501–11. doi: 10.1093/cvrv/cvu231

21. Sogo T, Morikawa K, Kurata Y, Li P, Ichinose T, Yuasa S, et al. Electrophysiological properties of JPS cell-derived cardiomycocytes from a patient with long QT syndrome type 1 harboring the novel mutation M437V of KCNQ1. *Regen Ther.* (2016) 4:9–17. doi: 10.1016/j.reth.2015.12.001

22. Bartos DC, Giudicessi JR, Tester DJ, Ackerman MJ, Ohno S, Horie M, et al. A KCNQ1 mutation contributes to the concealed type 1 long QT phenotype by limiting the Kv7.1 channel conformational changes associated with protein kinase A phosphorylation. *Heart Rhythm.* (2014) 11:459–68. doi: 10.1016/j.hrthm.2013.11.021

23. Shimizu W, Horie M, Ohno S, Takenaka K, Yamaguchi M, Shimizu M, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. *J Am Coll Cardiol.* (2004) 44:117–25. doi: 10.1016/j.jacc.2004.03.043

24. Ware JS, Walsh R, Cunningham F, Birney E, Cook SA. Paralogous annotation of disease-causing variants in long QT syndrome genes. *Hum Mutat.* (2012) 33:1188–91. doi: 10.1002/humu.22114

25. Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. *Circulation.* (2009) 120:1752–60. doi: 10.1161/CIRCULATIONAHA.109.865076

26. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. *Mayo Clin Proc.* (2003) 78:1479–87. doi: 10.4065/78.12.1479